Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 in BCG-unresponsive high-risk NMIBC
CTR20202169Phase 2Terminated
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in bladder cancer, sponsored by Taizhou Hanzhong Biomedical. Started Nov 2020; status: terminated.
02
Drugs
pucotenlimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20202169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202169.